Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors

Blood

Volumn 117, Issue 7, 2011, Pages 2179-2188

  Bretz, Jamieson ^a   Garcia, Josefina ^a,c   Huang, Xiangao ^a   Kang, Lin ^a   Zhang, Yang ^b   Toellner, Kai Michael ^b   Chen Kiang, Selina ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

^c California   (Peru)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; BIM PROTEIN; CD45 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2C; PROTEIN BCL 6; PROTEIN BCL XL; PROTEIN NOXA; SYNDECAN 1; BCL2L1 PROTEIN, MOUSE; CDKN2C PROTEIN, MOUSE; IMMUNOGLOBULIN G; PMAIP1 PROTEIN, HUMAN; PMAIP1 PROTEIN, MOUSE; PRDM1 PROTEIN, MOUSE; PROTEIN BCL 2; PROTEIN BCL X; SDC1 PROTEIN, MOUSE; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL CYCLE G1 PHASE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CONTROLLED STUDY; EMBRYO; GENE OVEREXPRESSION; HOMEOSTASIS; MOUSE; NONHUMAN; PLASMA CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; ANIMAL; B LYMPHOCYTE; BIOLOGICAL MODEL; BIOSYNTHESIS; C57BL MOUSE; CELL CYCLE; CELL STRAIN HEK293; CYTOLOGY; DRUG ANTAGONISM; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; METABOLISM; MOUSE MUTANT; PHYSIOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIGENS, CD45; APOPTOSIS; B-LYMPHOCYTES; BCL-X PROTEIN; CELL CYCLE; CELL DIFFERENTIATION; CYCLIN-DEPENDENT KINASE INHIBITOR P18; HEK293 CELLS; HEMATOPOIETIC STEM CELLS; HOMEOSTASIS; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MODELS, BIOLOGICAL; PLASMA CELLS; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-BCL-6; RNA, SMALL INTERFERING; SYNDECAN-1; TRANSCRIPTION FACTORS;

EID: 79951843773     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-06-288027     Document Type: Article

References (46)

1. Manz RA, Thiel A, Radbruch A. Lifetime of plasma cells in the bone marrow. Nature. 1997;388(6638):133-134. (Pubitemid 27297440)
2. Guan KL, Jenkins CW, Li Y, et al. Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. Genes Dev. 1994;8(24):2939-2952.
3. Hirai H, Roussel MF, Kato JY, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol. 1995;15(5):2672-2681.
4. Tourigny MR, Ursini-Siegel J, Lee H, et al. CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells. Immunity. 2002;17(2):179-189. (Pubitemid 35245960)
5. Mestre-Escorihuela C, Rubio-Moscardo F, Richter JA, et al. Homozygous deletions localize novel tumor suppressor genes in B-cell lymphomas. Blood. 2007;109(1):271-280. (Pubitemid 46053067)
6. Leone PE, Walker BA, Jenner MW, et al. Deletions of CDKN2C in multiple myeloma: biologic and clinical implications. Clin Cancer Res. 2008;14(19):6033-6041.
7. Shapiro-Shelef M, Lin KI, McHeyzer-Williams LJ, Liao J, McHeyzer-Williams MG, Calame K. Blimp-1 is required for the formation of immunoglobulin secreting plasma cells and preplasma memory B cells. Immunity. 2003;19(4):607-620. (Pubitemid 37311441)
8. Mittrücker HW, Matsuyama T, Grossman A, et al. Requirement for the transcription factor LSIRF/IRF4 for mature B and T lymphocyte function. Science. 1997;275(5299):540-543. (Pubitemid 27051911)
9. Reimold AM, Iwakoshi NN, Manis J, et al. Plasma cell differentiation requires the transcription factor XBP-1. Nature. 2001;412(6844):300-307. (Pubitemid 32691837)
10. Ye BH, Cattoretti G, Shen Q, et al. The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation. Nat Genet. 1997;16(2):161-170.
11. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 1997;276(5312):589-592. (Pubitemid 27193682)
12. Nera KP, Kohonen P, Narvi E, et al. Loss of Pax5 promotes plasma cell differentiation. Immunity. 2006;24(3):283-293.
13. Fujita N, Jaye DL, Geigerman C, et al. MTA3 and the Mi-2/NuRD complex regulate cell fate during B lymphocyte differentiation. Cell. 2004;119(1):75-86. (Pubitemid 39349321)
14. Lin KI, Angelin-Duclos C, Kuo TC, Calame K. Blimp-1-dependent repression of Pax-5 is required for differentiation of B cells to immunoglobulin M-secreting plasma cells. Mol Cell Biol. 2002;22(13):4771-4780. (Pubitemid 34620412)
15. Sciammas R, Shaffer AL, Schatz JH, Zhao H, Staudt LM, Singh H. Graded expression of interferon regulatory factor-4 coordinates isotype switching with plasma cell differentiation. Immunity. 2006;25(2):225-236. (Pubitemid 44224149)
16. Klein U, Casola S, Cattoretti G, et al. Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol. 2006;7(7):773-782. (Pubitemid 43905877)
17. O'Connor BP, Cascalho M, Noelle RJ. Short-lived and long-lived bone marrow plasma cells are derived from a novel precursor population. J Exp Med. 2002;195(6):737-745. (Pubitemid 34259718)
18. Toellner KM, Gulbranson-Judge A, Taylor DR, Sze DM, MacLennan IC. Immunoglobulin switch transcript production in vivo related to the site and time of antigen-specific B cell activation. J Exp Med. 1996;183(5):2303-2312. (Pubitemid 26158921)
19. Liu YJ, Zhang J, Lane PJ, Chan EY, MacLennan IC. Sites of specific B cell activation in primary and secondary responses to T cell-dependent and T cell-independent antigens. Eur J Immunol. 1991;21(12):2951-2962.
20. Jacob J, Kassir R, Kelsoe G. In situ studies of the primary immune response to (4-hydroxy-3- nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations. J Exp Med. 1991;173(5):1165-1175.
21. Franklin DS, Godfrey VL, Lee H, et al. CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev. 1998;12(18):2899-2911. (Pubitemid 28440148)
22. Bouillet P, Metcalf D, Huang DC, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999;286(5445):1735-1738. (Pubitemid 129515880)
23. Villunger A, Michalak EM, Coultas L, et al. p53-and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science. 2003;302(5647):1036-1038. (Pubitemid 37386194)
24. Fang W, Mueller DL, Pennell CA, et al. Frequent aberrant immunoglobulin gene rearrangements in pro-B cells revealed by a bcl-xL transgene. Immunity. 1996;4(3):291-299.
25. Do RK, Hatada E, Lee H, Tourigny MR, Hilbert D, Chen-Kiang S. Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response. J Exp Med. 2000;192(7):953-964.
26. Huang X, Di Liberto M, Cunningham AF, et al. Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. Proc Natl Acad Sci U S A. 2004;101(51):17789-17794. (Pubitemid 40051965)
27. Kim MY, Rossi S, Withers D, et al. Heterogeneity of lymphoid tissue inducer cell populations present in embryonic and adult mouse lym174.
28. Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13(12):1501-1512. (Pubitemid 29297917)
29. Allen CD, Ansel KM, Low C, et al. Germinal center dark and light zone organization is mediated by CXCR4 and CXCR5. Nat Immunol. 2004;5(9):943-952. (Pubitemid 39276239)
30. Hauser AE, Debes GF, Arce S, et al. Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol. 2002;169(3):1277-1282. (Pubitemid 34809169)
31. Su GH, Chen HM, Muthusamy N, et al. Defective B cell receptor-mediated responses in mice lacking the Ets protein, Spi-B. EMBO J. 1997;16(23):7118-7129. (Pubitemid 27520810)
32. Grillot DA, Merino R, Pena JC, et al. bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J Exp Med. 1996;183(2):381-391.
33. Altmeyer A, Simmons RC, Krajewski S, Reed JC, Bornkamm GW, Chen-Kiang S. Reversal of EBV immortalization precedes apoptosis in IL-6-induced human B cell terminal differentiation. Immunity. 1997;7(5):667-677. (Pubitemid 28156634)
34. Oda E, Ohki R, Murasawa H, et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science. 2000;288(5468):1053-1058. (Pubitemid 30324238)
35. Smith KG, Hewitson TD, Nossal GJ, Tarlinton DM. The phenotype and fate of the antibody-forming cells of the splenic foci. Eur J Immunol. 1996;26(2):444-448. (Pubitemid 26060254)
36. Morse L, Chen D, Franklin D, Xiong Y, Chen-Kiang S. Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. Immunity. 1997;6(1):47-56. (Pubitemid 27130214)
37. Ohtani K, DeGregori J, Nevins JR. Regulation of the cyclin E gene by transcription factor E2F1. Proc Natl Acad Sci U S A. 1995;92(26):12146-12150. (Pubitemid 26014027)
38. Phan RT, Saito M, Basso K, Niu H, Dalla-Favera R. BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat Immunol. 2005;6(10):1054-1060. (Pubitemid 41486191)
39. Shaffer AL, Yu X, He Y, Boldrick J, Chan EP, Staudt LM. BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity. 2000;13(2):199-212.
40. Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 2008;18(4):157-164.
41. Enders A, Bouillet P, Puthalakath H, Xu Y, Tarlinton DM, Strasser A. Loss of the proapoptotic BH3-only Bcl-2 family member Bim inhibits BCR stimulation-induced apoptosis and deletion of autoreactive B cells. J Exp Med. 2003;198(7):1119-1126. (Pubitemid 37248627)
42. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell. 2005;17(3):393-403. (Pubitemid 40193310)
43. Czabotar PE, Lee EF, van Delft MF, et al. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci U S A. 2007;104(15):6217-6222. (Pubitemid 47186075)
44. Gomez-Bougie P, Wuilleme-Toumi S, Menoret E, et al. Noxa up-regulation and Mcl-1 cleavage are associated to apoptosis induction by bortezomib in multiple myeloma. Cancer Res. 2007;67(11):5418-5424. (Pubitemid 46997282)
45. Qin JZ, Ziffra J, Stennett L, et al. Proteasome inhibitors trigger NOXA-mediated apoptosis in melanoma and myeloma cells. Cancer Res. 2005;65(14):6282-6293. (Pubitemid 40994414)
46. Pérez-Galán P, Roue G, Villamor N, Montserrat E, Campo E, Colomer D. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood. 2006;107(1):257-264. (Pubitemid 43053550)